The expression of inhibitor of apoptosis (IAP) family members contributes to the resistance of human cancers to apoptosis induced by radiotherapy and chemotherapy. We report that the infection of malignant glioma cells and several other tumor cell lines with adenoviruses encoding antisense RNA to X-linked IAP (XIAP) depletes endogenous XIAP levels and promotes global caspase activation and apoptosis. In contrast, non-neoplastic SV-FHAS human astrocytes and other non-neoplastic cells express XIAP at very low levels and resist these effects of adenovirusexpressing XIAP antisense RNA (Ad-XIAP-as). Caspase inhibitors such as z-Val-Ala-DL-Asp(OMe)-fluoromethylketone (zVAD-fmk) delay caspase processing and XIAP depletion, suggesting that XIAP depletion results both from antisense-mediated interference with protein synthesis and proteolytic cleavage by activated caspases. However, zVADfmk neither prevents nor delays cell death, indicating a caspase-independent pathway to cell death triggered by IAP depletion. Similarly, B-cell lymphoma-X L (BCL-X L ) inhibits caspase activity, but fails to rescue from apoptosis. Loss of p65/nuclear factor-kB (NF-kB) protein and NF-kB activity is an early event triggered by Ad-XIAP-as and probably involved in Ad-XIAP-as-induced apoptosis. Finally, Ad-XIAPas gene therapy induces cell death in intracranial glioma xenografts, prolongs survival in nude mice and may reduce tumorigenicity in synergy with Apo2L/TNF-related apoptosisinducing ligand (TRAIL) in vivo. Altogether, these data define a powerful survival function for XIAP and reinforce its possible role as a therapeutic target in human glioma cells.
Introduction
Resistance to induction of cell death by apoptosis in response to radiotherapy or chemotherapy is one of the hallmarks of many solid tumors including glioblastoma. For instance, many tumors overexpress members of the inhibitor of apoptosis (IAP) family, whereas IAP levels are rather low or absent in non-neoplastic cells. 1 IAPs were discovered in baculovirus where they substitute for the viral inhibitor p35 to suppress host cell death in response to viral infection. 2 IAP homologs were later isolated from fly, worm, yeast and mammalian cells. To date, at least seven members have been identified in mammalian cells: X-linked IAP (XIAP), 3 cellular IAP1 and -2 (cIAP1, cIAP2), 4 neuronal apoptosis inhibitory protein (NAIP), 3 survivin, 5 BIR repeat containing ubiquitin-conjugating enzyme 6 and melanoma/kidney IAP (ML-IAP/KIAP). 7 The principle mechanism underlying the antiapoptotic activity of IAP has been proposed to be by direct caspase inhibition. Several human IAP directly bind and inhibit members of the caspase family, for example, XIAP, cIAP1, cIAP2 and survivin directly target caspases-3, -7 and -9. 8 Further, IAP serve as ubiquitin ligases: they initiate ubiquitinylation of IAP-bound caspases and are therefore responsible for their proteasomal degradation. 9 The mitochondrial protein second mitochondrial activator of caspases (SMAC)/DIABLO promotes apoptosis by eliminating the protective effect of IAP through physical interactions, 10 which repress the ubiquitin ligase activity of XIAP and, to a lesser extent, of cIAP1 and cIAP2. 11 A second, alternative mechanism mediating XIAPdependent protection from apoptosis involves transcriptional activity mediated via the stimulation of NF-kB, which depends on the E3 ubiquitin ligase activity of the RING domain of XIAP.
12 NF-kB is composed of two subunits, p65relA and p50, which are members of the REL protein family. There are different pathways by which NF-kB can be activated: cytokines such as tumor necrosis factor-a (TNF-a) activate their receptor, and in turn recruit the complex of inhibitor of kB (IkB) kinase (IKK), resulting in IKK phosphorylation. IKK kinases include members of the mitogen-activated protein kinase kinase (MAPKK) family such as NF-kB-inducing kinase (NIK). An alternative pathway, induced by lymphotoxinb or B-cell growth factor, also activates NIK. Activation of IKK leads to the phosphorylation and degradation of IkB, releasing NF-kB to translocate into the nucleus. 13 The XIAP-mediated NF-kB activation also involves the phosphorylation and degradation of IkB, possibly by activation of IKK2 kinase.
14 XIAP may also be a cofactor in transforming growth factor (TGF)-b and bone morphogenic protein (BMP) signalling pathways where it binds to the cytoplasmic domain of the type I BMP receptor activin-like kinase-3. 15 Similarly, the association between XIAP and TGF-b receptor I results in the synergistic activation of TGF-b-dependent transcription. 16 Additionally, XIAP negatively modulates TNF-amediated, stress-responsive jun N-terminal kinase (JNK) activation, both through NF-kB-induced XIAP or cIAP2 upregulation 17, 18 and interaction between XIAP and TGF-b-activated protein kinase 1-binding protein. 15 XIAP-mediated activation of JNK involves the MAP3 kinase TGF-b-associated kinase (TAK)-1. 19 IAP gene amplifications and protein overexpression have been found in many human cancers including glioblastoma. 1, 20 The inhibition of IAP expression or activity might therefore be a promising strategy of cancer therapy. For instance, the inhibition of XIAP activity by small peptides or molecules mimicking the XIAP inhibitory activity of SMAC potentiates cell death induced by death ligands such as TNF-a Apo2L/TRAIL in vitro and in vivo, 21, 22 the constitutive expression of XAF enhances Apo2L/TRAIL-induced apoptosis in A375 melanoma cells 23 and the downregulation of XIAP protein levels by XIAP antisense oligonucleotides induces caspase-3 activity and apoptosis and promotes chemosensitivity in cultured human cancer cells. 24, 25 We here examined adenovirally mediated downregulation of XIAP protein expression in human malignant glioma cells as a strategy to induce apoptosis and to overcome glioma cell resistance to current modes of cancer therapy.
Results

XIAP-as-mediated depletion of XIAP induces apoptosis in human glioma cells
The infection of U87MG, LN-18 and LNT-229 cells with an adenovirus-expressing XIAP antisense RNA (Ad-XIAP-as) resulted in the loss of endogenous XIAP within 24 h. Non-neoplastic SV-FHAS human astrocytes did express only very low levels of XIAP, which was further reduced by Ad-XIAP-as ( Figure 1a ). The first changes in XIAP levels after infection with a multiplicity of infection (MOI) of 100 were noticed at 8-12 h, and even Ad-XIAPas infection at 30 MOI resulted in some XIAP loss at 12 h in LNT-229 cells (Figure 1b) . Ad-XIAP-as killed the majority of U87MG (p53 +/+ ), LN-18(p53 mut/mut ) and LNT-229(p53 +/+ ) cells in a time-and MOI-dependent manner, but had no effect on the growth of SV-FHAS cells (Figure 1c and d) . In contrast to hepatocellular carcinoma cells, 26 p53 seems to have no influence on Ad-XIAP-as-induced cell death in glioma cells, as either p53-wild-type U87MG-and LNT-229-, p53-mutant LN-18 or p53-deficient LN-308 cells (Figure 1c and d and data not shown) are killed by Ad-XIAP-as. That cell death and not merely growth inhibition were induced was verified by trypan blue dye exclusion (data not shown), quantification of DNA fragmentation ( Figure 1e ) and cell cycle analysis, which showed no specific cell cycle alteration after Ad-XIAP-as infection, but a dramatic increase in the sub-G 0/1 population, also indicating cell death (Figure 2 ). Morphologically, cell death induced by Ad-XIAP-as met classical features of apoptosis ( Figure 3 ). Early stages of apoptosis were characterized by the loss of the typical flat structure (LN-18, 8 h) , cell rounding and collapse of the nuclear membrane structure (LN-18, 12 h). Later stages of apoptosis were characterized by chromatin condensation and the dissolution of the nuclear structure (LNT-229, 16 h). At 24 h after Ad-XIAP-as infection, signs of apoptosis and secondary necrosis were seen in more than 95% of cells.
To determine whether the effects of Ad-XIAP-as were tumor cell-specific, a variety of other human cell lines, primary human tumor cells as well as non-tumor human cell lines and primary human non-tumor cells were infected with Ad-XIAP-as. All neuroglial and other cancer cell lines were killed, whereas non-tumor cell lines and human primary cells were unaffected (Table 1 and data not shown).
Ad-XIAP-as infection promotes caspase processing
The infection of LNT-229 cells with Ad-XIAP-as resulted in the rapid processing of caspases-3, -7 and -9 and of the caspase substrate, poly(ADP-ribose)polymerase (PARP). Coexposure to high concentrations of the broad-spectrum caspase inhibitor, z-Val-Ala-DL-Asp(OMe)-fluoromethylketone (zVAD-fmk), delayed caspase processing by some hours, but did not block caspase processing altogether, as, for example, in response to CD95L. 27 In contrast, the release of cytochrome c (Cyt c) from mitochondria triggered by Ad-XIAP-as was unaffected by zVAD-fmk. The loss of XIAP in response to Ad-XIAPas infection was delayed, albeit not prevented, by zVADfmk (Figure 4a ), suggesting that the loss of XIAP results not only from antisense-mediated inhibition of expression but also from active caspase-mediated proteolysis. 27 At several hours after infection, Cyt c and PARP, proteins with short half-life, were no more detected presumably because of impaired protein synthesis of the dying cells. The levels of human cIAP1 and cIAP2 were also strongly reduced when LNT-229 cells were infected with Ad-XIAP-as ( Figure 4b ). As reported previously, 20 human glioma cells do not express NAIP. The loss of cIAP1, but not of cIAP2, was inhibited by zVAD-fmk (Figure 4c ), confirming that caspase-mediated cleavage contributes to the rapid loss of IAP in response to Ad-XIAP-as.
The profile of caspase activity was assessed using the substrates ac-Asp-Glu-Ca-Asp-(7-amido-4-methylcoumarin) (DEVD-amc) for caspases-3 and -7, ac-Ile-GluPro-Asp-(7-amido-4-methylcoumarin) (IEPD-amc) for caspase-8 and ac-Leu-Glu-His-Asp-(7-amido-4-methylcoumarin) (LEHD-amc) for caspase-9. DEVD-amc-cleaving activity (Figure 5a ), but neither IEPD-amc-nor LEHD-amc-cleaving activity (data not shown), was induced by Ad-XIAP-as infection. Exposure to CD95L was used as a positive control for IEPD-amc-and LEHDamc-cleaving activity (data not shown). DEVD-amccleaving caspase activity was nullified in the presence Figure  5d ), unlike CD95L-induced apoptosis where zVAD-fmk blocks both caspase activity and cell death. 28 Finally, no alteration of the apoptotic morphology induced by Ad-XIAP-as was observed in the presence of zVAD-fmk (Figure 5e ). (e) LNT-229 cells were infected in triplicates at 100 MOI for 16 h or treated with CD95L (100 U/ml) plus CHX (10 mg/ml) for 6 h as a control. DNA fragmentation was quantified by differential fluorimetry of fragmented and intact DNA (one representative experiment). Ad-XIAP antisense gene therapy for malignant glioma U Naumann et al Human primary fibroblasts (no. 296, passage 3) 490 9379
Abbreviations: Ad-XIAP-as, adenovirus-expressing XIAP antisense RNA; EGFP, enhanced green fluorescence protein; PBMC, peripheral blood mononuclear cell; XIAP, X-linked inhibitor of apoptosis. The cells were exposed to Ad-EGFP or Ad-XIAP-as at 100 MOI. XIAP levels were assessed by immunoblot at 24 h. Note that, dependent on XIAP levels, the exposure length is variable between the different blots. The percentages of EGFP-positive cells were determined by flow cytometry at 48 h. Survival was estimated by crystal violet staining at 48 h (mean and s.e.m., n ¼ 3). a Surviving cells were growth arrested. b No detectable levels of XIAP protein.
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Role of BCL-2 family proteins during Ad-XIAP-asinduced apoptosis
B-cell lymphoma (BCL)-2 family proteins regulate apoptosis at the level of mitochondrial integrity and thus Cyt c-dependent caspase activation as well as probably additional, less well-defined pathways. 29 Further, the levels of BCL-2 family proteins may be altered during apoptosis, for example, by caspase cleavage. 27 Here, Ad-XIAP-as infection resulted in the cleavage of BCL-2-interacting domain (BID) at 10 h after infection. BCL-X L levels declined rapidly, whereas BCL-2 levels were unaffected by the loss of XIAP. The loss of BID and BCL-X L was zVAD-fmk-sensitive ( Figure 6a 
Role of NF-kB during Ad-XIAP-as-induced apoptosis
The proposed link between XIAP and NF-kB 14 provided a rationale for assessing a role of NF-kB in the cytotoxic effects of XIAP depletion. The loss of p65relA was among the earliest molecular events in response to Ad-XIAP-as infection. With a delay of 4-5 h, NF-kB p50 and IkB levels also decreased. The loss of IkB and p50, but not that of p65relA, was somewhat delayed by zVAD-fmk ( Figure  7a ). The loss of p65relA protein was accompanied by a gradual loss of NF-kB-associated reporter activity (Figure 7b ), which was not rescued by BCL-X L or zVAD-fmk (data not shown). Forced expression of p65relA by adenoviral gene transfer did not protect the cells from Ad-XIAP-as-induced apoptosis (Figure 7c ), even in the presence of adenovirally overexpressed NFkB-p50 or of zVAD-fmk (data not shown). Upon Adp65relA infection, both basic NF-kB reporter activity as well as p65relA protein levels increased, but both were lost during XIAP antisense expression (Figure 7d Ad-XIAP antisense gene therapy for malignant glioma U Naumann et al stronger effects were seen when the glioma cells were exposed to the NF-kB inhibitor, helenalin (Figure 7h ), which is thought to act by alkylating the p65relA subunit of NF-kB and thereby to inactivate NF-kB. 32 Accordingly, as a likely consequence of NF-kB inactivation, a downregulation of XIAP was observed (Figure 7i) , possibly being the proximate cause of helenalin-induced cell death.
Ad-XIAP-as gene therapy in a human glioma xenograft model in nude mice
To explore the effects of Ad-XIAP-as in vivo, orthotopic LNT-229 xenografts were treated with a single injection of Ad-XIAP-as. Compared with Ad-DE1, Ad-XIAP-as caused significant tissue destruction around the injection site within 16 h (Figure 8a and b) , accompanied by the downregulation of tumor-associated XIAP expression (Figure 8f ). There was a dramatic increase in active caspase-3-positive and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)-positive glioma cells around the injection region (Figure g-j) . Importantly, no changes in the levels of the rodent homologs, RIAP1, RIAP2 and RIAP3, were observed in mouse SMA-560 or rat CNS-1 glioma cells infected with Ad-XIAP-as (Figure 8k ). The enhanced green fluorescence protein (EGFP) signal from Ad-EGFP-control-infected cells was used to verify that the rodent glioma cell lines were infected as efficiently as the human cell lines (data not shown). The most efficient antisense sequence for human XIAP used here was thus of too low homology to the rodent homolog to allow the study of a rodent glioma model in vivo or to assess the possible toxicity of this approach in rodent cells including brain in vitro and in vivo. The single injection of Ad-XIAP-as prolonged the median survival relative to Ad-DE1-treated mice from 58 to 76 days (P ¼ 0.043, analysis of variance (ANOVA); Figure 8l ).
Ad-XIAP-as gene therapy combined with Apo2L.0: synergistic prolongation of survival
The dependence of death ligand-induced apoptosis on caspase activation, the prevention of this cell death pathway by adenoviral XIAP gene transfer 20 and the potentiation of Apo2L.0-induced apoptosis by SMACmimetic peptides 22 all predicted a synergistic interaction of Ad-XIAP-as and death ligands. However, owing to the rapid time kinetics of Ad-XIAP-as and death ligand killing and the somewhat variable onset of antisense expression, such synergy proved difficult to reproduce in culture (data not shown). We therefore chose a paradigm, which measures the reduction of tumorigenicity by coexposure to Ad-XIAP-as and Apo2L.0. U87MG cells, which, in contrast to LNT-229-cells, are moderately sensitive to Apo2L.0-induced cell death, were preinfected with Ad-XIAP-as, followed by treatment with Apo2L.0 6 h later and then implanted into the striatum of nude mice. Compared with Ad-DE1, either Apo2L.0 (P ¼ 0.01) or Ad-XIAP-as (P ¼ 0.047) increased the median survival from around 26 to around 42 days. The combination of Ad-XIAP-as and Apo2L.0 increased the median survival to 130 days (P ¼ 0.0006, compared with Ad-DE1). Synergy is difficult to evaluate in vivo, but the fractional product method 33 may be applied when the single effects are expressed as ratios of gains in survival, which correspond to values in the range of 1.3 for either treatment alone. The predicted increase in survival with co-treatment can then be calculated as 1.69, which is below the doubling of median survival observed with co-treatment ( Figure 9 ). These considerations would be compatible with the notion that there may be true synergistic inhibition of tumorigenicity resulting in prolonged survival when Ad-XIAP-as gene therapy is combined with Apo2L.0.
Discussion
Despite more than two decades of intense apoptosis research, few strategies of targeting apoptosis specifically to tumor cells have been developed to the stage of first clinical applications, for example, adenoviral p53 gene therapy or antisense oligonucleotides to BCL-2. The use of death ligands such as CD95L or Apo2L/TRAIL has been hampered both by a lack of specificity for tumor cells and by the expression of antiapoptotic proteins of the BCL-2 and IAP families. These proteins are also mediators of resistance to apoptosis in glioma cells. 20 Disruption of the interactions between IAP and caspases, which allows ensuing caspase activation, may be achieved by agonistic peptides mimicking the action of SMAC 22 or by SMAC mimetic pharmacological agents. 21 As a complementary approach, we here sought to promote glioma cell apoptosis using an antisense strategy targeting XIAP, encoded by adenoviruses. Apparently, this approach is much more powerful than the current SMAC agonists or small-molecule IAP inhibitors, suggesting that the function of short-lived molecules such as IAP can be targeted more efficiently at the level of gene expression than by competitive inhibition. Ad-XIAP-as expression in glioma cells resulted in the rapid loss of XIAP protein and the induction of cell death at low MOI in the absence of external death stimuli (Figures 1-3) , illustrating an essential survival function of XIAP in glioma cells. Similarly, antisense oligonucleotides to XIAP-induced death in the absence of external death stimuli in ovarian, 34 bladder, 24 lung 35 and prostate 25 cancer cells. Either antisense oligonucleotides to XIAP or RNA interference 36 also facilitated apoptosis induction by cytotoxic agents or death ligands in vitro 24, 25 and reduced tumor growth in a subcutaneous lung carcinoma xenograft model. 35 The rapid evolution of cell death made studies on the sensitization to radiotherapy or chemotherapy by Ad-XIAP-as difficult in our hands. However, the biochemical events mediating cell death in response to XIAP depletion alone have not been investigated in depth.
We observed that the depletion of XIAP led to the activation and processing of caspases, the generation of DEVD-amc-cleaving caspase activity and the release of Cyt c from the mitochondria (Figures 4a and 5a) . Despite the presumed role of XIAP in targeting caspases for proteasomal degradation, 9 the loss of XIAP did not result in an accumulation of procaspases, possibly because of autoactivation and autoprocessing. The loss of XIAP was delayed by the broad-spectrum caspase inhibitor, zVADfmk, suggesting that XIAP was not only depleted by antisense expression but also became a substrate for activated caspases, as previously observed during Ad-XIAP antisense gene therapy for malignant glioma U Naumann et al CD95L-induced apoptosis in these cells. 37 Interestingly, the expression of the homologs, cIAP1 and cIAP2, also decreased in response to Ad-XIAP-as expression ( Figure  4b ). Although the loss of these homologs may contribute to cell death, the molecular basis for their loss remains uncertain. It is conceivable that the antisense strategy employed to target XIAP also targeted cIAP1 and cIAP2 because of sequence homology. The delay of cIAP1 loss, but not cIAP2 loss, by zVAD-fmk (Figure 4c) is consistent with the observation that cIAP1, but not cIAP2, is a substrate for caspases during apoptosis. 38 Moreover, loss of positive transcriptional regulators of IAP such as NFkB 17,18 may account for the reduced levels of XIAP, cIAP1 and cIAP2 (Figure 7) . 
Ad-E1 + Ad-XIAP-as Ad-p65 + Ad-XIAP-as
Caspase cleavage assessed by immunoblot was delayed, but eventually not blocked by zVAD-fmk, whereas DEVD-amc cleavage was suppressed for up to 12 h (Figures 4 and 5) . At later time points after infection (12-24 h) in the presence of zVAD-fmk, there was a dissociation between the proteolytic cleavage detected by immunoblot and the prolonged suppression of DEVD-amc-cleaving activity, which we are unable to explain at present. Of note, the delay of caspase processing and the suppression of DEVD-amc-cleaving activity by zVAD-fmk did not translate into enhanced survival at any time point (Figure 5c and d) . Moreover, Ad-XIAP antisense gene therapy for malignant glioma U Naumann et al zVAD-fmk did not prevent the loss of Cyt c from mitochondria (Figure 4a) , which has been a strong predictor of cell death in various paradigms of glioma cell apoptosis. 27 Cyt c release from the mitochondria is thought to be controlled upstream by the caspase-mediated processing of BID. 39 In glioma cells, however, BID cleavage in response to CD95L occurred later than Cyt c release, 37 challenging this view. Accordingly, Cyt c release was unaffected by zVAD-fmk here, whereas BID cleavage was delayed (Figure 6a) , strongly supporting the view that BID does not control Cyt c release in glioma cell apoptosis triggered by death ligands or XIAP depletion. As previously observed in CD95L-treated glioma cells, 37 BCL-X L was probably a target for caspase-dependent degradation, whereas BCL-2 was not (Figure 6a ). However, similar to zVAD-fmk, BCL-X L gene transfer inhibited DEVD-amc cleavage, but neither mitochondrial Cyt c release nor cell death (Figure 6b-d) .
HE
Several lines of evidence suggest that the early loss of NF-kB in response to Ad-XIAP-as (Figure 7a and b) is a crucial step in the killing cascade. The survivalpromoting properties of NF-kB-dependent gene expression are well recognized. Here, inhibition of NF-kB alone by helenalin or DN-NIK inhibited glioma cell proliferation and promoted cell death (Figure 7h ). Similar effects have been observed with the expression of a constitutive active form of IkB and the cytotoxic effects of sulfasalazine have also been attributed to NF-kB inhibition. 40 The loss of p65relA was the earliest consequence of Ad-XIAP-as infection. It was unaffected by zVAD-fmk, indicating that p65relA is not a caspase target here. Coimmunoprecipitation failed to demonstrate a physical interaction of XIAP and p65 or p50 under reducing or non-reducing conditions where the interaction between p65 and p50 served as a positive control (data not shown). The molecular mechanism resulting in the loss of p65relA thus remains obscure. Its critical role in Ad-XIAP-as-induced cell death was confirmed by the observation that the co-infection with NIK-DN or IkBM accelerated cell death (Figure 7f and g ).
Few studies have addressed the role of IAP in the normal and diseased brain. The expression of XIAP, cIAP1 and cIAP2 in the rat brain has been documented by imunohistochemistry. XIAP was proposed to be expressed by neurons and a sub-population of oligodendrocytes. 41 Global ischemia promoted the expression of cIAP2 42 and loss of XIAP expression was linked to neuronal loss in an animal model of motor neuron disease. 43 The clinical perspective of IAP antisense gene therapy depends on the differential requirement for IAP as survival factors in normal versus neoplastic cells. Given the potential side effect of depleting a survivalpromoting gene product, a local mode of application as feasible in glioblastoma appears to be a reasonable strategy for a first application in man. As a proof-ofprinciple, we confirmed that Ad-XIAP-as induces caspase activation and TUNEL labeling in an orthotopic xenograft model in vivo and that a single application prolongs median survival (Figure 8 ). In the paradigm examined here, the effect of Ad-XIAP-as in the prolongation of survival was only moderate, putatively caused by the locally restricted infection of the tumor. Infection of tumor cells was high around the site of virus injection, whereas invading tumor cells were not or only poorly infected. In the setting of human glioblastoma, repetitive virus administrations and the use of superior application techniques such as convection-enhanced delivery could greatly improve the therapeutic benefit derived from this approach.
Building on our previous efforts to develop a death ligand-based treatment strategy for malignant glioma, we demonstrated a synergistic reduction of tumorigenicity by Ad-XIAP-as and Apo2L.0 (Figure 9 ), which is currently studied as a salvage treatment for patients with refractory cancer in a phase I setting. We were unable to assess the neurotoxicity of the antisense viruses used here because of their failure to downregulate rodent IAP expression (Figure 8k) . In general, possible neurotoxic side effects could be circumvented by using a gliomaspecific promoter to drive XIAP antisense expression. Moreover, in a clinical setting, anti-adenoviral immune response could both promote tumor cell killing and enhance toxicity.
Materials and methods
Materials, cell lines and viability assays
zVAD-fmk, DEVD-amc and zIEPD-amc were obtained from Bachem (Heidelberg, Germany). zLEHD-fmk was purchased from Calbiochem (Darmstadt, Germany). Cycloheximide (CHX) was from Sigma (Deisenhofen, Germany). Apo2L.0 was prepared by Genentech (South San Francisco, CA, USA). 44 pNF-kB-Luc, pMEKK and pRL-CMV were purchased from Stratagene (Amsterdam, The Netherlands). Helenalin was obtained from Biomol (Hamburg, Germany). Ad-XIAP-as was prepared by cloning human XIAP cDNA in antisense orientation into the adenoviral genome. Ad-p65/NF-kB (Ad-p65), Adp50/NF-kB (Ad-p50) and Ad-IkBM Ad-NIK-DN were kindly provided by PA Baker (McGill University, Ottawa, Canada). The generation of Ad-LacZ, Ad-DE1 and Ad-EGFP has been described. 45 LN-18, LNT-229 and U87MG human malignant glioma cells and SKN-BE neuroblastoma cells were kindly provided by N de Tribolet Ad-XIAP antisense gene therapy for malignant glioma U Naumann et al (Lausanne, Switzerland). Primary glioma cell lines were prepared as described. 46 SV-FHAS SV40-transformed human astrocytes were provided by A Muruganandam (Ottawa, Canada). HTC116 colon cancer cells were a kind gift of B Vogelstein (Baltimore, MD, USA), MCF7 breast carcinoma, DAOY medulloblastoma and Hela cervical carcinoma cells were obtained from American Type Culture Collection (Rockville, MD, USA). Primary human hepatocytes were kindly provided by M Schenk (Tü bingen, Germany), primary human vascular smooth muscle cells by D Siegel-Axel (Tü bingen, Germany) and primary human fibroblasts by C Weigert (Tü bingen, Germany). Peripheral blood mononuclear cells were prepared as described. 47 The mouse glioma cell line SMA-560 was provided by DD Bigner (Durham, NC, USA) and the rat CNS-1 glioma cell line was provided by WF Hickey (Lebanon, NH, USA). All cell lines, except HTC116, which grow in McCoys 5A medium, were maintained in Dulbecco's modified Eagle's medium (GIBCO Life Technologies, Eggenstein, Germany) containing 10% fetal calf serum, glutamine (2 mM) and penicillin (100 IU/ml)/streptomycin (100 mg/ml). Stably transfected, pooled LNT-229 cells expressing BCL-X L were generated as described. 37 
Adenoviral infection
Infection with recombinant viruses was accomplished by exposing cells to adenovirus in serum-free cell culture medium for 15 min followed by addition of serumcontaining medium for 1-4 days. Viral titers were assessed using the plaque-forming test (PFU) and counting infectious virus particles. 48 The efficacy of adenoviral gene delivery and expression was ascertained by EGFP fluorescence, b-galactosidase (LacZ) staining or immunoblot analysis. All glioma cell lines used here are uniformly and strongly EGFP-positive within 48 h at 100 MOI. 49 
Growth and viability assays
For proliferation and viability assays, the cells were seeded into 24-or 96-well plates and allowed to attach for 24 h. Growth and viability were assessed at different times or at variable MOI by crystal violet staining, trypan blue dye exclusion or cell cycle analysis. For cell cycle analysis, the cells were treated as indicated. Detached cells were harvested from the supernatant by centrifugation and added to the non-detached cells recovered by trypsination. The cells were washed with phosphatebuffered saline (PBS), fixed in 70% ice-cold ethanol, centrifuged and washed with PBS. The cells (10 6 / condition) were stained with propidium iodide (50 mg/ ml), diluted in PBS containing RNase A (100 mg/ml) and subjected to flow cytometric analysis of DNA content using a Becton Dickinson FACScalibur cytometer. Percentages of cells in the different cell cycle phases were calculated by CellQuest software (Becton Dickinson, Heidelberg, Germany). DNA fragmentation was quantified fluorimetrically. 50 
Immunoblot analysis
The general procedure has been described, 51 including the preparation of cytoplasmic lysates for the detection of Cyt c from mitochondria. 49 The following antibodies were used: anti-XIAP, anti-RIAP-1, -2 and -3, 52, 53 anticIAP1 (AF818, R&D Systems Europe, Belgium), anticIAP2 (AF817, R&D), anti-b-actin (I-19, Santa Cruz SC1616, Santa Cruz, CA, USA), anti-BCL-X L (556492A, Pharmingen-Becton Dickinson, Heidelberg, Germany), anti-BCL-2 (N19, Santa Cruz SC492), anti-BAX (N20, Santa Cruz SC493), anti-IkB (6A920, Alexis, Grü nberg, Germany), anti-NF-kB-p65 (F6, Santa Cruz SC8008), anti-NF-kB-p50 (H119, Santa Cruz SC7178), anti-HA (Y11, Santa Cruz SC805), anti-caspase-3 (No. C31720, Transduction Laboratories, Lexington, KY, USA), anti-caspase-8 (PH Krammer, Heidelberg, Germany), anti-caspase-7 and -9 (Y Lazebnik, New York, NY, USA), and anti-Cyt c (65981A), anti-crm-A (clone A71-1, no. 556427) and anti-PARP (clone 4C10-5, no. 556494) (all Pharmingen-Becton Dickinson).
Caspase activity assay
The cells were seeded at 10 4 cells/well in microtiter plates and allowed to attach. At 24 h after infection, the cells were lysed and substrate was added. 45 Fluorescence was measured at 1-6 h after lysis using a cytofluor II fluorimeter (Perkin-Elmer, Weiterstadt, Germany).
Luciferase reporter assay
The cells were grown at 10 4 cells/well in microtiter plates. Attached cells were transfected with 160 ng pNF-kB-Luc and 20 ng pRL-CMV as an internal standard. As a positive control, the cells were co-transfected with 40 ng pMEKK. At 48 h after transfection, the cells were infected with 100 MOI Ad-LacZ or Ad-XIAP-as for increasing time periods. NF-kB activity was assessed according to the manufacturer's instructions. Counts were normalized to cell density determined by crystal violet staining.
Electron microscopy
The cells were seeded in six-well plates, allowed to attach, infected as indicated, fixed in 2.5% glutaraldehyde in Hank's modified salt solution, postfixed in 1% OsO 4 in 0.1 M cacodylate buffer, scraped off and dehydrated in a series of ethanol. The 70% ethanol step was saturated with uranyl acetate for contrast enhancement. Dehydration was completed in propylene oxide and the specimens were embedded in Araldite (Serva, Heidelberg, Germany). Ultrathin sections were produced on an FCR Reichert Ultracut ultramicrotome (Leica, Bensheim, Germany), mounted on pioloform-coated copper grids and contrasted with lead citrate. Specimens were analyzed and documented with an EM 10A electron microscope (Zeiss, Oberkochen, Germany).
Animal studies
Female athymic mice (CD1 nu/nu , Charles River, Sulzfeld, Germany) aged 6-8 weeks were anesthetized with 7% chloral hydrate and placed in a stereotactic fixation device (Stoelting, Wood Dale, IL, USA). A burr hole was drilled in the skull 2 mm lateral to the bregma. The needle of a Hamilton syringe (Hamilton, Darmstadt, Germany) was introduced to a depth of 3 mm. The cells (7.5 Â 10 4 /animal) suspended in 4 ml PBS were injected into the right striatum. At 7 days after implantation, the mice were again placed in the stereotactic fixation device and 10 8 PFU of adenovirus in PBS were slowly injected using the coordinates of tumor cell inoculation. The mice were observed daily and killed by an overdose of anesthetic when developing neurological symptoms for Ad-XIAP antisense gene therapy for malignant glioma U Naumann et al the survival studies or at predetermined time points for histological analysis. All animal work was carried out in accordance with the NIH guidelines' Guide for the Care and Use of Laboratory Animals' and with Section 8, Section 1 of the law for treatment of animals in Germany and approved by the local authorities (N3/03, Regierungspräsidium Tü bingen, Germany).
Immunhistochemistry XIAP (610763; Becton Dickinson) and active caspase-3 (AF835; R&D Systems, Europe, Belgium) were detected by immunohistochemistry. Briefly, the tumor sections were deparaffinized and rehydrated in an ethanol gradient. Tissues were pretreated with 3% H 2 O 2 in methanol to block endogenous peroxidase and boiled for 10 min in citrate buffer. Endogenous biotin activity was blocked with the DAKO biotin blocking kit (DAKOCytomation GmbH, Hamburg, Germany). Sections were blocked with 3% skim milk and 10% normal swine serum for 30 min each at room temperature. Primary antibodies were added and the tissue sections were incubated overnight at 41C in a humidified chamber. For each tissue tested, purified normal immunoglobulin G substituted for the specific antibody served as a negative control. The sections were washed three times with PBS containing 0.05% Tween 20 (PBST). For the detection of caspase-3, biotinylated goat antirabbit secondary antibody (Vector Laboratories, Burlingham, CA, USA) was added for 1 h. After three PBST washes, streptavidin peroxiase conjugate (Zymed, Berlin, Germany) was added and the tissue sections were incubated for 10 min, washes with PBST and 3-amino-9-ethylcarbazole in N,N-dimethylformamide (Zymed) was added as a substrate. After further 10 min of incubation, the sections were washed with water. For the detection of XIAP, the Mouse Elite Kit Detection System, the VECTASTAIN s Universal ABC-AP Kit and diaminobenzidine (Vector Laboratories, Burlingame, CA, USA) were used. TUNEL staining was performed using the TUNEL-AP Kit (Roche, Basel, Switzerland). Neighboring control sections were stained using Mayer's hematoxylin. All sections were coverslipped and staining was assessed by light microscopy.
Statistical analysis
The figures show data obtained in two or three independent experiments as indicated. Quantitative data were assessed for significant differences using t-test and ANOVA.
